Angle PLC, a U.K. liquid-biopsy company, has witnessed a significant rise in its shares following a groundbreaking announcement. The company revealed that DNA molecular analysis conducted on blood samples from cancer patients has provided valuable insights into the progression and treatment of various types of cancers. This breakthrough not only expands Angle PLC’s product sales but also strengthens its pharmaceutical service offerings.
At 0834 GMT, Angle PLC shares experienced an impressive surge of 41% in early trade. The value of the shares rose by 4.50 pence, equivalent to a 34% increase, reaching 17.75 pence. The shares even peaked at a high of 18.63 pence during the session. However, it is worth noting that despite this recent upswing, the shares have declined by 63% over the past year.
The results obtained from DNA analysis encompassed a total of 47 patient samples, specifically focusing on breast, lung, prostate, and ovarian cancers. CEO Andrew Newland emphasized the significance of this breakthrough, stating that it represents a critical advancement following the clearance from the Food and Drug Administration (FDA). This breakthrough showcases the potential clinical value of next-generation sequencing (NGS) molecular analysis, which can be conducted repeatedly on cancer cells harvested from living patient blood samples.
Such groundbreaking developments pave the way for more effective cancer treatments and a better understanding of the disease’s progression. Angle PLC’s research in DNA molecular analysis is undoubtedly a remarkable step forward in the field of oncology.